middle.news
Noxopharm Signs MoU and Appoints New CEO to Boost Sofra Platform
9:46am on Friday 24th of April, 2026 AEST
•
Biotechnology
Read Story
Noxopharm Signs MoU and Appoints New CEO to Boost Sofra Platform
9:46am on Friday 24th of April, 2026 AEST
Key Points
MoU with Tezcat Biosciences to explore targeted drug delivery
Sofra RNA platform featured in Nature Immunology journal
Dr Olivier Laczka appointed CEO to drive Sofra development
HERACLES trial dosing completed with positive safety results
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE